GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer

Jing Yang, Jing Wen, Tian Tian, Zhongsheng Lu, Yao Wang, Zikai Wang, Xiangdong Wang, Yunsheng Yang, Jing Yang, Jing Wen, Tian Tian, Zhongsheng Lu, Yao Wang, Zikai Wang, Xiangdong Wang, Yunsheng Yang

Abstract

Background: Glucose transporter-1 (GLUT-1) exhibits altered expression in colorectal cancer (CRC). The aim of this study was to explore the association between GLUT-1 and survival conditions, as well as clinical features in CRC by meta-analysis.

Materials and methods: Relevant studies were searched through predefined strategies, hazard ratios (HRs), odds ratios (ORs), and their 95% confidence intervals (CIs) were used as effective measures.

Results: A total of 14 studies with 2,077 patients were included in this meta-analysis. The results showed that GLUT-1 was not significantly associated with overall survival (OS) (HR=1.28, 95% CI=0.86-1.91, p=0.22) or disease-free survival (DFS) (HR=1.71, 95% CI=0.78-3.72, p=0.179). However, subgroup analysis indicated that GLUT-1 was a significant biomarker for poor DFS in rectal cancer (HR=2.47, 95% CI=1.21-5.05, p=0.013). GLUT-1 expression was also found to be significantly correlated with the presence of lymph node metastasis (n=8, OR=2.14, 95% CI=1.66-2.75, p<0.001), T stage (n=6, OR=1.73, 95% CI=1.17-2.58, p=0.007), higher Dukes stage (n=5, OR=2.92, 95% CI=2.16-3.95, p<0.001), female sex (n=4, OR=2.92, 95% CI=2.16-3.95, p<0.001), and presence of liver metastasis (n=3, OR=1.82, 95% CI=1.06-3.12, p=0.03).

Conclusion: In conclusion, this meta-analysis showed that GLUT-1 was associated with poor DFS in rectal cancer (RC). Furthermore, GLUT-1 was also an indicator of aggressive clinical features in CRC.

Keywords: GLUT-1; biomarker; colorectal cancer; meta-analysis; survival.

Conflict of interest statement

CONFLICTS OF INTEREST

The authors confirm that there are no conflicts of interest.

Figures

Figure 1. Flow diagram for articles included…
Figure 1. Flow diagram for articles included in this meta-analysis
Figure 2. Forest plot diagrams of hazard…
Figure 2. Forest plot diagrams of hazard ratios for correlations between GLUT-1 expression and OS
The forest plot was stratified by cancer type. The pooled HR and 95%CI for OS were on the overall horizontal line. The horizontal axis indicates the pooled HR. ES (effect size) is HR in this figure.
Figure 3. Forest plot diagrams of hazard…
Figure 3. Forest plot diagrams of hazard ratios for correlations between GLUT-1 expression and DFS
The forest plot was stratified by cancer type. The pooled HR and 95%CI for DFS were on the overall horizontal line. The horizontal axis indicates the pooled HR. ES (effect size) is HR in this figure.
Figure 4. Association between GLUT-1 expression and…
Figure 4. Association between GLUT-1 expression and clinicopathological parameters in CRC
A. lymph node metastasis; B. differentiation; C. T stage; D. Dukes stage; E. sex; F. age; G. tumor size; H. liver metastasis.
Figure 5. Publication bias in the meta-analysis
Figure 5. Publication bias in the meta-analysis
A. Begg's test for OS; B. Egger's test for OS; C. Begg's test for DFS; D. Egger's test for DFS.

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386.
    1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365:153–165.
    1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–117.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
    1. Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 2010;298:E141–145.
    1. Saier MH, Jr, Beatty JT, Goffeau A, Harley KT, Heijne WH, Huang SC, Jack DL, Jahn PS, Lew K, Liu J, Pao SS, Paulsen IT, Tseng TT, Virk PS. The major facilitator superfamily. J Mol Microbiol Biotechnol. 1999;1:257–279.
    1. Carruthers A, DeZutter J, Ganguly A, Devaskar SU. Will the original glucose transporter isoform please stand up! Am J Physiol Endocrinol Metab. 2009;297:E836–848.
    1. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, Bartenstein P, Wagner W, Whiteside TL. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–1024.
    1. Sasaki H, Shitara M, Yokota K, Hikosaka Y, Moriyama S, Yano M, Fujii Y. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol Med Rep. 2012;5:599–602.
    1. Maki Y, Soh J, Ichimura K, Shien K, Furukawa M, Muraoka T, Tanaka N, Ueno T, Yamamoto H, Asano H, Tsukuda K, Toyooka S, Miyoshi S. Impact of GLUT1 and Ki-67 expression on earlystage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification. Oncol Rep. 2013;29:133–140.
    1. Yuan HZ, Zhan BL, Zhang GL. Expression of Glut1 and MVD in colorectal carcinoma and its relationship with liver metastasis. China Cancer. 2003:59–61.
    1. Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001;60:162–169.
    1. Lastraioli E, Bencini L, Bianchini E, Romoli MR, Crociani O, Giommoni E, Messerini L, Gasperoni S, Moretti R, Di Costanzo F, Boni L, Arcangeli A. hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. Transl Oncol. 2012;5:105–112.
    1. Hong R, Lim SC. (1)(8)F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol. 2012;18:168–174.
    1. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34–40.
    1. Cooper R, Sarioglu S, Sokmen S, Fuzun M, Kupelioglu A, Valentine H, Gorken IB, Airley R, West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer. 2003;89:870–876.
    1. Zhou YL, Deng CS. Correlations of expressions of Glut1 and HIF-1alpha to cellular proliferation of colorectal adenocarcinoma. Chin J Cancer. 2005;24:685–689.
    1. Cleven AH, van Engeland M, Wouters BG, de Bruine AP. Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol. 2007;29:229–240.
    1. Wincewicz A, Sulkowska M, Koda M, Sulkowski S. Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer. Pathol Oncol Res. 2007;13:15–20.
    1. Havelund BM, Sorensen FB, Lindebjerg J, Spindler KL, Jakobsen A. Pretreatment HIF-1alpha and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer. Anticancer Res. 2011;31:1559–1565.
    1. Jun YJ, Jang SM, Han HL, Lee KH, Jang KS, Paik SS. Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas. World J Gastroenterol. 2011;17:1866–1873.
    1. Korkeila EA, Sundstrom J, Pyrhonen S, Syrjanen K. Carbonic anhydrase IX, hypoxia-inducible factor-1alpha, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer: multivariate Cox survival models following data reduction by principal component analysis of the clinicopathological predictors. Anticancer Res. 2011;31:4529–4535.
    1. Shim BY, Jung JH, Lee KM, Kim HJ, Hong SH, Kim SH, Sun DS, Cho HM. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Colorectal Dis. 2013;28:375–383.
    1. Goos JA, de Cuba EM, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, Belien JA, Menke-Van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Ann Surg. 2016;263:138–145.
    1. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
    1. Egger M, G Davey Smith, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
    1. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res. 1989;49:3759–3764.
    1. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med. 2010;14:771–794.
    1. Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaiba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG, Soares FA. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011;66:965–972.
    1. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci. 1999;56:285–292.
    1. Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer. 2002;38:51–57.
    1. Harshani JM, Yeluri S, Guttikonda VR. Glut-1 as a prognostic biomarker in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2014;18:372–378.
    1. Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, IW da Cunha, Lourenco SV, Soares FA. GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. Molecules. 2010;15:2374–2387.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834.
    1. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj